4 Healthcare Stock Stories Prescribed for Investors

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Neurocrine Biosciences (NASDAQ:NBIX): Closing price $9.19

On Wednesday the company announced that two additional patents have been granted related to its proprietary Vesicular Monoamine Transporter 2 inhibitor NBI-98854. European Patent Number 2,081,929 was granted in January by the European Patent Office, with an expiry date of November 2027, covering chemical compositions, pharmaceutical compositions and also uses of various compounds, among which include the firm’s Phase IIb clinical candidate NBI-98854. Additionally, the United States Patent and Trademark Office recently granted a second patent for NBI-98854.


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business